Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome
详细信息 查看全文
- 作者：Federico Lussana1 ; flussana@asst-pg23.it" class="auth_mail" title="E-mail the corresponding author ; Tamara Intermesoli1 ; Francesca Gianni1 ; Cristina Boschini1 ; Arianna Masciulli1 ; Orietta Spinelli1 ; Elena Oldani1 ; Manuela Tosi1 ; Anna Grassi1 ; Margherita Parolini1 ; Ernesta Audisio2 ; Chiara Cattaneo3 ; Roberto Raimondi4 ; Emanuele Angelucci5 ; Irene Maria Cavattoni6 ; Anna Maria Scattolin7 ; Agostino Cortelezzi8 ; Francesco Mannelli9 ; Fabio Ciceri10 ; Daniele Mattei11 ; Erika Borlenghi3 ; Elisabetta Terruzzi12 ; Claudio Romani5 ; Renato Bassan7 ; Alessandro Rambaldi1 ; 13
- 关键词：Acute lymphoblastic leukemia ; Allogeneic transplantation ; Minimal residual disease (MRD)
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：22
- 期：11
- 页码：1983-1987
- 全文大小：765 K
文摘
- •
Minimal residual disease positivity in acute lymphoblastic leukemia is a major risk factor for relapse and poor outcomes
- •
We evaluated the impact of minimal residual disease levels before allogeneic hematopoietic stem cell transplantation on outcomes for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
- •
Patients with measurable levels of minimal residual disease have a higher risk of relapse
- •
Achieving minimal residual disease negativity should be a prerequisite for successful allogeneic hematopoietic stem cell transplantation